![]() |
市場調查報告書
商品編碼
1933388
全球凝血分析儀市場:市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考量因素以及未來預測(2026-2034)Coagulation Analyzers Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034 |
||||||
預計2025年全球凝血分析儀市場規模將達39億美元,2026年成長至41.2億美元,最終在2034年達到66.5億美元,預測期間內複合年增長率(CAGR)為6.16%。北美地區將引領市場,2025年市場佔有率將達到35.47%,這主要得益於其完善的醫療保健基礎設施、血液疾病盛行率的上升以及先進凝血檢測設備的日益普及。
凝血分析儀是一種用於測量血液凝固能力和凝固速度的醫療檢測設備。 它們對於監測接受華法林等抗凝血治療的患者以及檢測包括血友病在內的凝血相關疾病至關重要。心血管疾病和血栓形成的發病率上升,以及外科手術數量的增加,正在推動對這些分析儀的需求不斷增長。西門子醫療、希森美康、羅氏和沃芬等主要市場參與者正在積極推出產品、建立合作關係,以鞏固其市場地位。
市場動態
市場驅動因素
血液疾病盛行率上升
凝血相關疾病(尤其是血友病)發病率的上升,以及人口老化和不健康生活方式的增加,正在推動對凝血檢測的需求。醫院和診斷實驗室擴大採用自動化凝血分析儀,以實現準確、快速和可靠的診斷,並改善患者的治療效果。 此外,對即時檢測 (POC) 的需求不斷增長,正在改善接受抗凝血治療患者的檢測可及性。根據珀斯血液研究所的數據,截至 2025 年 7 月,全球血友病患病率約為每 6,000 至 10,000 名男性中就有 1 例,其中 A 型血友病的盛行率為每 5,000 人中 1 例,B 型血友病的患病率為每 30,000 人中 11 例。
市場限制因子
先進系統和試劑成本高
自動化凝血分析儀的普及受到高昂的初始投資和維護成本的限制。具備多參數檢測、自動化和連接功能的先進型號價格昂貴,而持續的試劑和校準成本進一步增加了營運成本。在資源有限的環境中,實驗室往往依賴手動或半自動系統,這限制了效率和準確性,從而減緩了市場滲透。
市場機會
個人化醫療與新一代分析設備
個人化抗凝血治療,包括華法林和直接口服抗凝血劑 (DOAC) 的個人化劑量,推動了對精準凝血監測的需求。基因譜分析和基於人工智慧的預測分析的整合,正在提升個性化患者護理水平,並為三級醫療中心和研究機構的新一代凝血分析儀創造了豐厚的市場機會。
市場趨勢
轉型為全自動化和即時偵測 (POC) 系統
醫療機構正擴大採用高通量、全自動分析儀進行即時多參數檢測,以減少人為誤差。同時,用於急救和快速檢測的便攜式即時檢測分析儀的需求也在不斷增長。 例如,2021年10月,Trivitron Healthcare和Diagon-Vanguard Diagnostics在印度推出了一系列凝血分析儀,透過自動化、易操作性和內建的品質控制功能,為臨床決策提供支援。
市場挑戰
熟練實驗室技術人員短缺
新興市場面臨訓練有素的實驗室技術人員短缺的問題,這些技術人員需要操作複雜的分析儀、進行校準並確保品質控制。這種人才短缺降低了效率,限制了利用率,並影響了診斷準確性。世界衛生組織預測,到2030年,全球將出現1,100萬醫護人員缺口,主要集中在低收入和中低收入國家,這將影響市場擴張。
依產品劃分
市場依系統(自動化、半自動化和手動)和耗材細分。 由於自動化系統需要使用特定試劑,耗材部分預計在2026年將佔31.71%的市佔率。系統部分預計將以5.8%的複合年增長率成長。
依技術劃分
光學檢測憑藉其準確性和可重複性,在2025年佔市場主導地位,預計在2026年將佔60.64%的市場佔有率。機電檢測預計將以6.3%的複合年增長率成長。
依偵測類型劃分
凝血酶原(PT)檢測部分預計將在2025年佔最大的市場佔有率,並在2026年保持30.87%的市場佔有率,這主要歸功於其在監測抗凝血治療和診斷凝血障礙方面的重要作用。 D-二聚體檢測預計將以6.3%的複合年增長率成長。
依最終使用者劃分
醫院在2025年佔市場主導地位,並在2026年維持38.13%的市佔率。這主要歸功於分析設備的高普及率和龐大的患者群體。預計診斷實驗室的複合年增長率將達到6.5%。
北美市場在2025年將達到13.8億美元,預計到2026年將增長至14.6億美元,這主要得益於其完善的醫療保健基礎設施以及美國超過6000家醫院。
預計歐洲市場在2025年將達到11.6億美元,主要得益於其大量的診斷實驗室。 預計到 2026 年,英國、德國和法國的市場規模將分別達到 2.3 億美元、2.8 億美元和 1.9 億美元。
預計到 2025 年,亞太地區的市場規模將達到 11 億美元,而到 2026 年,印度和中國的市場規模將分別達到 1.4 億美元和 4.7 億美元。到 2025 年,拉丁美洲和中東及非洲地區的市場規模將分別達到 1.6 億美元和 8,000 萬美元。
The global coagulation analyzers market was valued at USD 3.90 billion in 2025 and is projected to grow to USD 4.12 billion in 2026, ultimately reaching USD 6.65 billion by 2034, reflecting a CAGR of 6.16% during the forecast period. North America dominated the market in 2025 with a 35.47% share, driven by the presence of well-established healthcare infrastructure, rising prevalence of hematological disorders, and the increasing adoption of advanced coagulation testing devices.
Coagulation analyzers are medical laboratory instruments that measure how well and how quickly blood clots. They are critical for monitoring patients on anticoagulant therapies, such as warfarin, and for detecting coagulation-related disorders, including hemophilia. The rising incidence of cardiovascular diseases, thrombosis, and increasing surgical procedures have accelerated the demand for these analyzers. Major market players, such as Siemens Healthineers AG, Sysmex, F. Hoffmann-La Roche Ltd., and Werfen, are actively engaged in product launches, partnerships, and collaborations to strengthen their market presence.
Market Dynamics
Market Drivers
Rising Prevalence of Hematological Disorders
The increasing incidence of coagulation-related disorders, particularly hemophilia, and an aging population with unhealthy lifestyles have intensified the demand for coagulation testing. Hospitals and diagnostic laboratories are increasingly adopting automated coagulation analyzers to enable accurate, rapid, and reliable diagnosis, improving patient outcomes. Additionally, the growing demand for point-of-care (POC) testing enhances accessibility for patients undergoing anticoagulant therapy. According to the Perth Blood Institute, as of July 2025, the global prevalence of hemophilia was approximately 1 in 6,000-10,000 males, with hemophilia A affecting 1 in 5,000 and hemophilia B affecting 1 in 30,000.
Market Restraints
High Cost of Advanced Systems and Reagents
The adoption of automated coagulation analyzers is hindered by high capital and maintenance costs. Advanced models with multi-parameter testing, automation, and connectivity features are expensive, and recurring reagent and calibration costs further increase operational expenditures. In low-resource settings, laboratories often rely on manual or semi-automated systems, which limits efficiency and accuracy, slowing market penetration.
Market Opportunities
Personalized Medicine and Next-Generation Analyzers
Tailored anticoagulant therapies, including individualized dosing of warfarin and direct oral anticoagulants, drive the need for precise coagulation monitoring. Integration with genetic profiling and AI-enabled predictive analytics is enhancing personalized patient care, creating lucrative opportunities for next-generation coagulation analyzers in tertiary hospitals and research institutions.
Market Trends
Shift to Fully Automated and Point-of-Care Systems
Healthcare facilities increasingly prefer high-throughput, fully automated analyzers for real-time, multi-parameter testing, reducing human error. Simultaneously, portable POC analyzers are gaining traction for emergency care and rapid testing. For example, in October 2021, Trivitron Healthcare and Diagon-Vanguard Diagnostics launched a range of coagulation analyzers in India, supporting clinical decision-making with automation, ease of operation, and built-in quality control.
Market Challenges
Shortage of Skilled Laboratory Personnel
Emerging markets face a shortage of trained laboratory staff to operate complex analyzers, conduct calibration, and ensure quality control. This staffing gap reduces efficiency, limits utilization, and affects diagnostic accuracy. The WHO projects a global healthcare workforce shortfall of 11 million by 2030, mainly in low- and lower-middle-income countries, impacting market expansion.
By Product
The market is divided into systems (automatic, semi-automatic, manual) and consumables. The consumables segment accounted for 31.71% share in 2026, driven by the adoption of automated systems requiring system-specific reagents. The systems segment is projected to grow at a CAGR of 5.8%.
By Technology
Optical detection dominated in 2025 due to its accuracy and reproducibility, holding a 60.64% share in 2026. Electromechanical detection is projected to grow at a CAGR of 6.3%.
By Test Type
The prothrombin (PT) test segment captured the largest share in 2025 and is projected to hold 30.87% in 2026, due to its critical role in monitoring anticoagulant therapy and diagnosing coagulation disorders. D-dimer testing is expected to grow at a CAGR of 6.3%.
By End-User
Hospitals dominated in 2025 and held a 38.13% share in 2026, owing to higher installation rates of analyzers and large patient inflows. Diagnostic laboratories are projected to grow at a CAGR of 6.5%.
North America led with USD 1.38 billion in 2025, growing to USD 1.46 billion in 2026, supported by established healthcare infrastructure and over 6,000 hospitals in the U.S.
Europe reached USD 1.16 billion in 2025, driven by numerous diagnostic laboratories, with the U.K., Germany, and France at USD 0.23 billion, USD 0.28 billion, and USD 0.19 billion in 2026.
Asia Pacific was valued at USD 1.10 billion in 2025, with India and China at USD 0.14 billion and USD 0.47 billion in 2026. Latin America and Middle East & Africa reached USD 0.16 billion and USD 0.08 billion, respectively, in 2025.
Competitive Landscape
Key market players include Siemens Healthineers AG, Sysmex, F. Hoffmann-La Roche Ltd., Werfen, Helena Laboratories, Beckman Coulter, Meril Life Sciences, HORIBA, BIOLABO, and Diagon. Companies focus on new product launches, partnerships, and global expansion to maintain market leadership. Recent developments include:
Conclusion
The global coagulation analyzers market is expected to grow from USD 4.12 billion in 2026 to USD 6.65 billion by 2034, driven by rising prevalence of hematological disorders, adoption of automated and POC analyzers, and the shift toward personalized medicine. North America dominates the market, while Europe and Asia Pacific exhibit significant growth potential. Challenges such as high system costs and skilled workforce shortages remain, but technological advancements and integration with AI and genetic profiling continue to offer lucrative opportunities for market expansion.
Segmentation By Product, Technology, Test Type, End-user, and Region
By Product * Systems
By Technology * Optical Detection
By Test Type * Prothrombin
By End-user * Hospitals
By Region * North America (By Product, Technology, Test Type, End-user, and Country)